Symbol="YMAB"
AssetType="Common Stock"
Name="Y mAbs Therapeutics"
Description="Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of new antibody-based therapeutics for the treatment of cancer in the United States. The company is headquartered in New York, New York."
CIK="1722964"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="750 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="240347000"
EBITDA="-35933000"
PERatio="None"
PEGRatio="None"
BookValue="2.4"
DividendPerShare="0"
DividendYield="0"
EPS="-0.86"
RevenuePerShareTTM="1.946"
ProfitMargin="-0.46"
OperatingMarginTTM="-0.433"
ReturnOnAssetsTTM="-0.155"
ReturnOnEquityTTM="-0.331"
RevenueTTM="84986000"
GrossProfitTTM="57700000"
DilutedEPSTTM="-0.86"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.922"
AnalystTargetPrice="11.75"
TrailingPE="-"
ForwardPE="119.05"
PriceToSalesRatioTTM="5.21"
PriceToBookRatio="2.056"
EVToRevenue="2.523"
EVToEBITDA="-0.852"
Beta="0.678"
num_52WeekHigh="17.02"
num_52WeekLow="2.7"
num_50DayMovingAverage="6.32"
num_200DayMovingAverage="5.64"
SharesOutstanding="43620200"
DividendDate="None"
ExDividendDate="None"
symbol="YMAB"
open="5.52"
high="5.63"
low="5.34"
price="5.39"
volume="106868.00"
latest_trading_day="2023-08-30"
previous_close="5.51"
change="-0.12"
change_percent="-2.1779%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="21"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="79"
Volume_recent_avg="304156"
Change_recent_avg="-0.03"
Delta_recent_avg="0.54"
Variance_recent_avg="0.27"
Change_ratio_recent_avg="-0.52"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="79"
Aroon_momentum_negative="21"
image_negative_thumbnail_id_1="1106"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0139.jpeg"
image_negative_thumbnail_id_2="104"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0072.jpeg"
image_neutral_thumbnail_id_1="583"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0016.jpeg"
image_neutral_thumbnail_id_2="596"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0003.jpeg"
image_positive_thumbnail_id_1="953"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0115.jpeg"
image_positive_thumbnail_id_2="699"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0009.jpeg"
image_professor_thumbnail_id_1="1200"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0034.jpeg"
image_professor_thumbnail_id_2="1175"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0009.jpeg"
